tbuckley/cabot-search huggingface dataset:
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.
Authors: Victor Moreno, Emiliano Calvo, Maria Eugenia Olmedo Garcia, Marta Gil-Martin, Raid Aljumaily, Kyriakos P. Papadopoulos, Lee S. Rosen, Petra Rietschel, Kosalai Kal Mohan, Jingjin Li, Elizabeth Stankevich, Tracey Rowlands, Minjie Feng, Matthew G. Fury
Journal: Journal of Clinical Oncology (2019)

116 Background: NSCLC accounts for ~85% of lung cancers; most patients (pts) are at an advanced stage at the time of diagnosis. Cemiplimab (REGN2810) is being investigated for the treatment of NSCLC, in addition to other indications (NCT02383212). Methods: In the dose escalation (DE) phase, enrolled pts with advanced malignancies with no alternative standard-of-care therapeutic option received cemiplimab 1, 3 or 10 mg/kg every 2 weeks (Q2W) intravenously (IV) for up to 48 weeks. In the NSCLC expansion cohort (EC 1), enrolled pts with advanced disease who had relapsed after, or were refractory to at least first-line therapy received cemiplimab 200 mg Q2W IV for up to 48 weeks. Tumor biopsies were performed at baseline (EC 1 only), Day 29 and progression, if possible. Tumor measurements were performed every 8 weeks according to RECIST 1.1. Results: As of Sept 1, 2017, 21 pts with NSCLC (1 in DE at 1 mg/kg; 20 in EC 1) were enrolled; median age was 65.0 years (range, 50–82; 14 M/ 7 F); 81.0% had a ECOG performance status of 1, 19.0% of 0; 13/21 (61.9%) had a histology of adenocarcinoma. The most common treatment-related adverse events (TRAEs) were asthenia, pneumonitis, and rash (each n = 3, 14.3%). Each of the following ≥Grade 3 TRAEs occurred once: pneumonitis, diabetic ketoacidosis, and nephritis. By central independent review, 6 pts had partial response (PR), 6 had stable disease (SD) or non-complete response (CR)/non-progressive disease (PD), and 9 had PD. Overall response rate (ORR; CR + PR) was 28.6%. Duration of response exceeded 8 months in 5 of the 6 responders. Disease control rate (ORR + SD) was 57.1%. Disease control has been maintained for 7 pts after a planned treatment completion at 48 weeks. Of the 17 pts who had tissue available for PD-L1 expression evaluation, 11 (64.7%) had a tumor proportion score (TPS) of &lt; 1%, and 3 (17.6) had a TPS of &gt; 50%. Conclusions: Cemiplimab showed an acceptable safety profile and demonstrated antitumor activity in pretreated pts with NSCLC. Pivotal trials of cemiplimab as monotherapy or in combination with other treatments in pts with advanced NSCLC are currently enrolling (NCT03088540; NCT03409614). Clinical trial information: NCT02383212.
Saturday, March 16, 1985, 3:00–5:00 pm Workshop 4. Systemic mast cell disorders
Authors: Elliot Ellis, Clifton Furukawa, Joann Blessing-Moore, Gary Rachelefsky, Brian Butcher, Lars Aukrust, Carol O'neil, Margaret Reed, Dean Metcalfe
Journal: Journal of Allergy and Clinical Immunology (1985)
Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).
Authors: Richard A. Adams, David Fisher, Susan Farragher, Alastair Scott, Christopher G Smith, Michelle D James, Jeremy Cheadle, Laura L Nichols, Angela M. Meade, Richard S. Kaplan, Richard H. Wilson, Harpreet S Wasan, Tim Maughan
Journal: Journal of Clinical Oncology (2012)

3516 Background: Previous data suggest the EGF ligands EREG/AREG may predict outcome of KRAS wt patients (pts) in the chemo-refractory setting but has not been previously reported from first line randomised trials. Methods: FFPE samples from primary tumors of pts in Arms A&amp;B of the COIN trial of Ox fluoropyrimidine (Fp) +/- cet were analysed for EGFR IHC, KRAS/NRAS/BRAF mutation and EREG/AREG expression by RT-PCR. Ligand levels were assessed against baseline data, prognostic markers as uni/multivariate analyses and as predictive markers in wild type (wt) and mutant (mt) cohorts and separately by Fp backbone [capecitabine (CapOx) or 5FU (FOLFOX)]. Tests for interaction were performed with EREG/AREG continuous, using Flexible Parametric survival analysis. Optimal cutoffs for predictive effects were defined using point at which 95% CI first excluded zero. Results: 952/1630 (57%) of pts were evaluable for all parameters. EREG/AREG were highly correlated Pearson’s rho (ρ) = 0.74; p&lt;0.0001. High EREG/AREG levels were associated with KRAS wt (p&lt;0.005) and with primary tumor in left colon/rectum, presence of liver metastases and high CEA (p&lt;0.05). In the control arm, high EREG/AREG conferred a better prognosis among KRAS wt pts in multivariate. EREG superseded AREG in a combined model. High EREG predicted for OS benefit in KRAS wt pts treated with FOLFOX +cet, with optimal cut-off 80th centile. OS HR for ±cet ≥80th centile =0.33, 95% CI 0.14-0.78, p=0.011; &lt;80% centile HR=0.99, 95% CI 0.67-1.47, p=0.96; interaction p=0.059; ≥50th centile HR=0.66, 95% CI 0.40-1.09, p=0.11; &lt;50% centile HR=1.09, 95% CI 0.66-1.81, p=0.73; interaction p=0.17. Similar results were seen for PFS, with optimal cut-off 50th centile. There was no predictive effect for pts treated with CapOx. Conclusions: The data suggest a prognostic effect of EREG/AREG in aCRC. The original hypothesis, that KRAS wt patients with high EREG expression have improved outcome with cet, seems to be limited to patients treated with FOLFOX in the first-line setting.
State Medical Associations and Examinations and Licensure
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population
Authors: M. B. Edmonson
Journal: JAMA (1990)

A prolonged school-based outbreak of measles provided an opportunity to study "vaccine-modified" mild measles and secondary vaccine failure. Thirty-six (97%) of 37 unvaccinated patients had rash illnesses that met the Centers for Disease Control clinical case definition of measles, but 29 (15%) of 198 vaccinated patients did not, primarily because of low-grade or absent fever. Of 122 patients with seroconfirmed measles, 10 patients (all previously vaccinated) had no detectable measles-specific IgM and significantly milder illness than either vaccinated or unvaccinated patients with IgM-positive serum. Of 108 vaccinated patients with seroconfirmed measles, 17 patients (16%) had IgM-negative serology or rash illnesses that failed to meet the clinical case definition; their mean age (13 years), age at the time of vaccination, and time since vaccination did not differ from those of other vaccinated patients. The occurrence of secondary vaccine failure and vaccine-modified measles does not appear to be a major impediment to measles control in the United States but may lead to underreporting of measles cases and result in overestimation of vaccine efficacy in highly vaccinated populations. (<i>JAMA</i>. 1990;263:2467-2471)
Special Article.IMMUNITY.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mixed Reviews for New AML Drugs
Journal: Cancer Discovery (2018)

Of two new FDA-approved therapies for acute myeloid leukemia (AML), hematologists expect that the FLT3/AXL inhibitor gilteritinib will likely become an integral part of treatment. However, they think glasdegib, which targets the Sonic hedgehog pathway, may have limited utility, because it must be prescribed alongside cytarabine, an uncommon AML treatment option in the United States.
Development of a novel retroviral vector transferring a suicide gene driven by a tetracycline-responsive expression system (TRES) Norris Cancer Center, USC, School of Medicine, LA
Journal: Hepatology (1995)

The aim of this work was to introduce a tetracycline-responsive (Tet-off) gene expression system into myoblasts in order to regulate a reporter gene not only in vitro but also particularly in muscles implanted with these engineered myoblasts. Mouse myoblasts from a long-term culture (i28 cells) were transfected initially to generate and characterize two stable master clones expressing tetracycline-responsive transactivator protein tTA. Like parental i28 myoblasts, these clones differentiated well in vitro. The second step introduced the firefly (Photinus pyralis) luciferase gene into one of the stable tTA clones producing double transfectants expressing luciferase in the absence of tetracycline. Addition of tetracycline (1 μg ml−1) resulted in at least 100-fold decreases in luciferase activity within 8 h in both growing and differentiating myoblast cultures. Enzyme activity was rapidly restored after tetracycline was removed (8 h). After successful implantation of these myoblasts into damaged mouse muscles, luciferase expression in the matured progeny cells could be regulated by oral application of doxycycline for at least 1 month. The tetracycline-responsive master clones are potentially powerful tools for studying the function of various genes in postnatal myogenesis.
THE DEFINITION OF EPILEPSY.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Community care.
Authors: I Philp, J Dunleavey
Journal: BMJ (1993)

even exceeds 50%.6 Britain has the highest pro- portion of population over 75 of any country in Europe.The World Health Organisation-International Society of Hypertension guidelines for initiating treatment in hypertension include a six month period of monthly reviews.8Is it seriously suggested that the entire elderly population should be regularly screened, that a clear majority should be followed up monthly for six months, and that half should be treated for life on the basis of even the most optimistic interpretation of the trial data?I submit that there are logistical, financial, and indeed ethical questions to be addressed first.
Corrigenda
Authors: Thos Fletcher, G Maclaren, S Steele, T Piethorn, R King, Victor Poulain De Bois Angers, Middlesex Brompton, Hugh Broughton, Edmund Brown, Sloane Square, Chelsea William, Henchman Clubbe, Suffolk Beccles, Christopher Robert, Newcastle-On-Tyne Frost, John Ridge, Kent Gravesend, Alfred Taylor
Journal: BMJ (1850)

that gentleman pervade every rank of society in the parish of Weston: indeed, the kindness and skill which he displayed, in his treatment of cholera patients, was such as to merit the warmest approbation of all who had an opportunity of observing the exemplary manner in which he discharged his professional duties on that tryiing occasion.
Abstract 2729: Atrogin-1 and MuRF1 Mediate Degradation of Cardiac Myosin-binding Protein C by the Ubiquitin-Proteasome System
Authors: Giulia Mearini, Christina Gedicke, Elisabeth Krämer, Friedrich Buck, Peirang Cao, Christian Witt, Stewart Lecker, Siegfried Labeit, Thomas Eschenhagen, Lucie Carrier
Journal: Circulation (2007)

Background. Familial hypertrophic cardiomyopathy (FHC) is a sarcomeropathy frequently associated with cardiac myosin-binding protein C (cMyBP-C) gene mutations. Most of them result in a frameshift and C-terminal truncated proteins. However, truncated mutants were not detected in myocardial tissue of FHC patients. A recent study showed that a truncated cMyBP-C (M7t) is rapidly and quantitatively degraded by the ubiquitin-proteasome system (UPS) after adenoviral gene transfer in neonatal rat cardiac myocytes (NRCM). Since the diversity and specificity of UPS regulation lies in E3 ubiquitin ligases, which specifically target proteins and direct the ubiquitination process, the present study investigated whether the sarcomere-specific E3 ligases, atrogin-1 and MuRF1, mediate degradation of wild-type (WT) and truncated M7t cMyBP-C. Methods and Results. NRCM were co-infected with atrogin-1 and WT or M7t cMyBP-C adenoviruses. Both overexpressed WT and M7t were co-immunoprecipitated with atrogin-1 suggesting that both forms of cMyBP-C interact with atrogin-1. However, whereas the amount of overexpressed WT cMyBP-C did not change, the M7t protein level was 80% lower in NRCM infected with atrogin-1 than without. This suggests that atrogin-1 is the E3 ligase mediating proteasome degradation of truncated M7t cMyBP-C only. We then investigated whether MuRF1 could regulate the level of endogenous cMyBP-C in MuRF1-KO mice and compared to WT. The heart to body weight ratio and the chymotrypsine-like activity of the proteasome were similar in KO and WT mice. The mRNA levels of cMyBP-C, and other E3 ligases, atrogin-1 and MuRF3, were similar between KO and WT ventricles. Strikingly, the protein level of cMyBP-C was 150% and 30% higher in neonatal and 24 wks-old KO compared to age-matched WT mice. Conclusion . These data suggest that atrogin-1, located at the Z-band, mediates the proteasome degradation of truncated M7t cMyBP-C resulting from a FHC mutation, the lack of MuRF1 is not compensated by other E3 ligases and is not associated with hypertrophy in KO mice, and most importantly, MuRF1, mainly located at the M-band, specifically regulates the protein level of cMyBP-C.
Filler
Journal: BMJ (2002)

home."In this category, incidents described in general terms such as "collapse" fell from 35% to 20%, whereas those attributed more specifically to cardiac problems rose from 22% to 31% and those attributed to respiratory problems from 12% to 21% (see table C on bmj.com).We thank members of Wiltshire Ambulance Services Trust who provided data, tea, and moral support during long days of searching for records.
Experimental Coronary Arteriography. I. The Distribution and Extent of Allylamine-Induced Vascular Lesions in the Dog
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Iris as Pharmacologic Indicator
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JOSEPH SKODA (1805-1881)— PHYSICAL DIAGNOSTICIAN
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patients with chronic urticaria have a higher risk of psychiatric disorders: a population‐based study
Authors: C.Y. Chu, Y.T. Cho, J.H. Jiang, C.C. Chang, S.C. Liao, C.H. Tang
Journal: British Journal of Dermatology (2020)

Chronic urticaria (CU) is a skin disease which causes itchy hives that last for at least six weeks. It is a common disease that affects 0.6 to 0.8% of the general population worldwide. CU can affect people's quality of life, performance at school, and work. Although a few recent studies have investigated the association of psychiatric disorders and urticaria, the relative risk of various psychiatric disorders and the usage of psychiatric medications among CU patients in a large population is largely unknown. In this study, the authors aimed to investigate the prevalence (how common it is) and relative risks of psychiatric disorders or psychiatric medication use among CU patients by CU severity level. This is a population-based study from Taiwan. The authors found that CU patients had a 1.43-fold to 2.32-fold higher risk of psychiatric disorders, and had more frequent psychiatric medication prescription, compared to the general population. The authors concluded that mental health evaluations and management are important elements in CU management. This summary relates to the study: Patients with chronic urticaria have a higher risk of psychiatric disorders: a population-based study
P16.02 Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial
Authors: F. W. Boele, M. Klein, I. M. Verdonck-de Leeuw, P. Cuijpers, J. J. Heimans, T. J. Snijders, M. J. Vos, I. Bosma, C. C. Tijssen, J. C. Reijneveld
Journal: Neuro-Oncology (2016)
THE FLY AND THE TUBERCLE BACILLUS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal